Cargando…
To blind or not to blind first in human and exploratory clinical trials: Acceleration of development vs. risk of bias
An IQ consortium working group (WG) conducted a survey across multiple biopharmaceutical companies to gain information about the level of blinding commonly utilized for early clinical development trials. The main objectives were: (1) to understand blinding practices between healthy volunteer (HV) an...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932719/ https://www.ncbi.nlm.nih.gov/pubmed/34786861 http://dx.doi.org/10.1111/cts.13200 |